Company intelligence
Cardiawave
Cardiawave is developing an innovative and non-invasive ultrasound treatment of aortic stenosis.
About Cardiawave
Innovation prize winner of many contests, Cardiawave is a clinical-stage company which develops an innovative non-invasive image-guided medical device (MD) to treat aortic valve stenosis with ultrasound technology. Aortic stenosis is a life-threatening disease which is a major public health concern in Western countries (10 million people affected). The MD uses focused ultrasound therapy to soften aortic valve leaflets and improve valve opening. The company was created at the end of 2014 as a result of a long-term partnership between the Langevin Institute / Physics for Medicine Paris, a world leader in ultrasound imaging and therapy, and the Georges Pompidou European Hospital (HEGP), a leader in the field of valve disease and cardiac ultrasound imaging.
Verified activity
Signals from Cardiawave
5 published signals
Research & Knowledge
Cardiawave published the 12-month results from the Pivotal study evaluating Valvosoft® noninvasive ultrasound therapy for patients with severe symptomatic calcific aortic stenosis.
Reported by Cardiawave
People
Cardiawave is hiring a Senior Mechanical Design Technician in Levallois-Perret, France.
Reported by Cardiawave
People
Cardiawave is hiring a Senior Embedded Software Engineer in Levallois-Perret, France.
Reported by Cardiawave
People
Cardiawave is hiring a Quality & Regulatory Affairs Project Manager in Levallois-Perret, France.
Reported by Cardiawave
Presence & Recognition
Cardiawave highlighted the continued deployment of Valvosoft for the treatment of severe symptomatic calcific aortic stenosis in patients not recommended for immediate Transcatheter or Surgical Aortic Valve Replacement (TAVR/SAVR) at CHU de Rouen.
Reported by Cardiawave